Supporting information

Asymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis

Diana Buitrago-Garcia, Dianne Egli-Gany, Michel J Counotte, Stefanie Hossmann, Hira Imeri,
Mert Aziz Ipekci, Georgia Salanti, Nicola Low Institute of Social and Preventive Medicine, University
of Bern, Bern, Switzerland

Item	Title	Page
S1 Text	Search strings	1
S1 Table	Types of study included in successive versions of the living systematic review, as of 10 June 2020	3
S2 Table	Location of studies contributing data to review questions 1 and 2	4
S1 Figure	Flow chart	5
S2 Figure	Review question 1, forest plot of included studies, by study precision	6
S3 Figure	Risk of bias in studies included in review question 1 and 2	7
S4 Figure	Review question 2, forest plot of included studies, by study precision	8
S5 Figure	Sub-group analysis, review question 1, comparing studies of hospitalised patients with all other settings	9
S6 Figure	Sensitivity analysis, review question 1, omitting studies that were preprints at the time of literature search	10
S7 Figure	Assessment of credibility of mathematical modelling studies	11
S1 PRISMA	Checklist	12

S1 Text. Search strings

From: Living Evidence on COVID-19 (https://ispmbern.github.io/covid-19/living-review/collectingdata.html, accessed 10.06.2020)

We retrieve data from EMBASE via OVID, MEDLINE via PubMed, BioRxiv and MedRxiv.

Search terms

When searches are updated, references that are identified that were not in the database before, are inserted by date (date_entrez) they were indexed in remote database, the date they are inserted in OUR database is formatted as the 'strategydate' (raw data is available here).

01.05.2020

EMBASE:

(SARS coronavirus/ or middle east respiratory syndrome/ or severe acute respiratory syndrome/ or (coronavirus* or corona virus* or HCoV* or ncov* or covid or covid19 or sars-cov* or sarscov* or Sars-coronavirus* or Severe Acute Respiratory Syndrome Coronavirus*).mp.) and 20191201:20301231.(dc).

29.04.2020

MEDLINE:

```
("coronavirus"[MH] OR "coronavirus infections"[MH] OR "coronavirus"[TW] OR "corona virus"[TW] OR "HCoV"[TW] OR "nCov"[TW] OR "covid"[TW] OR "covid19"[TW] OR "Severe Acute Respiratory Syndrome Coronavirus 2"[TW] OR "SARS-CoV2"[TW] OR "SARS-CoV2"[TW] OR "SARS-CoV2"[TW] OR "MERS-CoV"[TW]) AND (2019/1/1:3000[PDAT])
```

01.04.2020

From 01.04.2020, we retrieve the currate BioRxiv/MedRxiv dataset Link

26.03.2020

MEDLINE:

```
("Wuhan coronavirus" [Supplementary Concept] OR "COVID-19" OR SARS-CoV-2 OR "2019 ncov"[tiab] OR (("novel coronavirus"[tiab] OR "new coronavirus"[tiab]) AND (wuhan[tiab] OR 2019[tiab])) OR 2019-nCoV[All Fields] OR (wuhan[tiab] AND coronavirus[tiab]))
```

EMBASE:

(nCoV or 2019-nCoV or ((new or novel or wuhan) adj3 coronavirus) or covid19 or covid-19 or SARS-CoV-2).mp.

BioRxiv/MedRxiv:

ncov or corona or wuhan or COVID or SARS-CoV-2

With the kind support of the <u>Public Health & Primary Care Library PHC</u>, and following guidance of the <u>Medical Library Association</u>

01.01.2020

MEDLINE:

```
("Wuhan coronavirus" [Supplementary Concept] OR "COVID-19" OR "2019 ncov"[tiab] OR (("novel coronavirus"[tiab] OR "new coronavirus"[tiab]) AND (wuhan[tiab] OR 2019[tiab])) OR 2019-nCoV[All Fields] OR (wuhan[tiab] AND coronavirus[tiab])))))
```

EMBASE:

ncov OR (wuhan AND corona) OR COVID

BioRxiv/MedRxiv:

ncov or corona or wuhan or COVID

We retained publications that used the keywords listed below in the title or abstract.

"asymp*" OR "pre-symp*" OR "presymp*" OR "preclinical" OR "pre-clinical" OR "without symptoms" OR "no symptoms" OR "free of symptoms" OR "non-symp*" OR "nonsymp*" OR "symptom-free" OR "symptomfree"

S1 Table. Changes over time in types of evidence about asymptomatic SARS-CoV-2 infection. Number of new studies identified, by date of search

Version	Version 1	Version 2	Version 3	Overall
Search date	25.03.2020	20.04.2020	10.06.2020	
Observational studies				
Contact investigation	6	4 ^a	7	17 ^a
Evacuation	2^{b}	••		
Contact investigation, aggregated		2	7 ^c	9°
Outbreak investigation		4 ^c	8	12
Screening		4 ^b	4	8 ^b
Hospitalised adults		8 ^d	10	18 ^d
Hospitalised children		3	7	10
Hospitalised adults and children			10	10
Secondary attack rate ^e		••	1 ^e	1
Statistical modelling	1	0	0	1
Mathematical modelling	2	2	4	8
Total	11	25 ^b	58	94

Footnotes refer to specific studies, where data from one version have been updated in a new publication. Citations use the number of the study in the reference list in the main text.

- a. In version 3, one study (Le TQM [30]) does not appear in forest plot because participants were included in a larger study (Wong J [103]), which was categorised with hospitalised adults)
- b. In version 2, studies of evacuees re-distributed into new categories: screening (Arima Y [28], which replaces Nishiura H [25]) and hospitalised adults (Tabata S [27]). In overall column total, include in their new category. In column total for version 2, these studies are not included because they were not newly identified studies;
- c. In version 3, one study (Kimball A [35]) replaced (by Arons M [58]) with updated data
- d. In version 3, one study (Breslin N [29]) replaced (by Andrikopoulou [56]) with updated data
- e. New category in version 3. Chaw L [65] contributes data only to calculation of secondary attack rate. Four studies in other categories also contribute to this analysis

S2 Table. Country in which studies were done to estimate proportions of asymptomatic and pre-symptomatic SARS-CoV-2 infections

Review question 1, proportion of asymptomatic infection

Country	Number of studies ^a	SARS-CoV-2 cases, total
China	44	3619
Germany	6	174
South Korea	5	619
USA	5	298
Italy	3	556
United Kingdom	3	200
India	2	465
Brunei	1	138
Cruise Ship	1	104
France	1	13
Iraq	1	15
Japan	1	12
Malaysia	1	4
Saudi Arabia	1	128
Spain	1	16
Taiwan	1	22
Thailand	1	11
Vietnam	1	208
Total	79	6602

Review question 2: proportion of pre-symptomatic infection

Asymptomatic SARS-CoV-2 cases

Country	Number of studies ^a	at time of testing, total
China	14	353
South Korea	3	75
USA	3	104
Germany	2	8
Japan	2	48
Brunei	1	138
Greece	1	39
Italy	1	39
Malaysia	1	2
United Arab Emirates	1	7
United Kingdom	2	60
Total	31	873

^a A study can contribute data to more than one review question.

Figure S1. Flow chart of identified, excluded and included records as of 10 June 2020

^a Numbers of new records at each search: 1st search, 25.03.2020; 2nd search, 20.04.2020; 3rd search, 10.06.2020

^b Duplicate records are identical articles in different databases, found after automated de-duplication

c 11 studies were included in the first review and 37 studies were included in the first update

d Study by Mizumoto et al. in qualitative synthesis but not included in forest plot

Study	Events	Total		Prop.	95% CI
Tong, ZD [cluster:1]	1	2		0.50	[0.01;0.99]
Hoehl, S Huang, R	1	2		0.50 0.50	[0.01;0.99] [0.01;0.99]
Jiang, XL [cluster:2]	1	2	- :	0.50	[0.01;0.99]
Jiang, XL [cluster:3] Jiang, X	1 1	2		0.50 0.33	[0.01;0.99] [0.01;0.91]
Liao, J [cluster:2]	1	3	 	0.33	[0.01;0.91]
Tong, ZD [cluster:2] Hu, Z	2	3 4	- 	0.67 0.25	[0.09;0.99] [0.01;0.81]
Luo, SH	1	4	- ∷ •	0.25	[0.01;0.81]
See, KC Jiang, XL [cluster:1]	1	4 4	- 	0.25 0.25	[0.01;0.81] [0.01;0.81]
Liao, J [cluster:3]	1	4	- 	0.25	[0.01;0.81]
Chan, JF Liao, J [cluster:1]	1 1	5 5	├ 	0.20 0.20	[0.01;0.72] [0.01;0.72]
Ye, F	1	5	- :	0.20	[0.01;0.72]
Bai, Y Luo, Y	1 5	6 6	 8: 	0.17 0.83	[0.00;0.64] [0.36;1.00]
Pongpirul, WA	1	11	 	0.09	[0.00;0.41]
Hijnen, D Danis, K	1	11 13	 	0.09 0.08	[0.00;0.41] [0.00;0.36]
Böhmer, MM	1	16		0.06	[0.00;0.30]
Zou, L Chang, L	1 2	18 4	H 	0.06 0.50	[0.00;0.27] [0.07;0.93]
Zhang, J	2	5	⊢ ; 	0.40	[0.05;0.85]
Zhang, B Huang, L	2 2	7 7	 	0.29 0.29	[0.04;0.71] [0.04;0.71]
Qian, G	2	8		0.25	[0.03;0.65]
Roxby, AC	3 2	6 10		0.50 0.20	[0.12;0.88]
Yang, N Tan, YP	2	10	· · · · ·	0.20	[0.03;0.56]
Schwierzeck, V	2	12 13		0.17 0.15	[0.02;0.48] [0.02;0.45]
Tan, X Brandstetter, S		36	 -	0.06	[0.02,0.45]
Melgosa, M	2 3 3	16	 	0.19 0.13	[0.04;0.46]
Wu, HP Arima, Y	4	23 12	 	0.33	[0.03;0.34] [0.10;0.65]
Zhang, W2	4	12	 	0.33	[0.10;0.65]
Arons, MM Cheng, HY	3 4	47 22	——————————————————————————————————————	0.06 0.18	[0.01;0.18] [0.05;0.40]
Gao, Y	6	15	 	0.40	[0.16;0.68]
Merza, MA Wang, Z	6 4	15 47		0.40 0.09	[0.16;0.68] [0.02;0.20]
Yongchen, Z	5	21		0.24	[0.08;0.47]
Park, SY Song, W	4 8	97 16		0.04 0.50	[0.01;0.10] [0.25;0.75]
Dora, AV	6	19	- 	0.32 0.17	[0.13;0.57]
Rivett, L Qiu, C	5 5	30 104	—	0.17	[0.06;0.35] [0.02;0.11]
Tian, S	7	24	 	0.29 0.32	[0.13;0.51]
Bai, K Zhou, R	8 9	25 31	 	0.32	[0.15;0.54] [0.14;0.48]
Xu, H	11	32		0.34 0.28	[0.19;0.53]
Qiu, H Wu, J	10 8	36 83	+⊞	0.20	[0.14;0.45] [0.04;0.18]
Luo, L	8	129		0.06 0.23	[0.03;0.12]
Ma, Y Kim, SE	11 10	47 71	+ = :	0.23	[0.12;0.38] [0.07;0.24]
Treibel, TA	12	44	⊢: □ + □ -	0.27 0.10	[0.15;0.43]
Solbach, W Chang, MC	10 10	97 139	母 :	0.10	[0.05;0.18] [0.04;0.13]
Zhou, X	10 10	328 345		0.03 0.03	[0.01;0.06] [0.01;0.05]
Angelo Vaira, L Choe, PG	15	113	——————————————————————————————————————	0.13	[0.08;0.21]
Bi, Q	17 14	87 1012	→ □ → :	0.20 0.01	[0.12;0.29] [0.01;0.02]
Wang, X Wong, J	16	138		0.12	[0.07;0.18]
Xu, T London, V	15 22	342 68		0.04 0.32	[0.02;0.07] [0.22;0.45]
Sharma, AK	215	234	-	0.92	[0.88;0.95]
Lavezzo, E Yang, R	29 33	73 78	⊢ □ →	0.40 0.42	[0.28;0.52] [0.31;0.54]
Zhang, W3	26	137	- -	0.19	[0.13;0.27]
Lu, Y	29 33	110 104	!: □ - : ! - □ - 1	0.26 0.32	[0.18;0.36] [0.23;0.42]
Tabata, S Lombardi, A	41	138		0.30	[0.22;0.38]
Graham, N	46 69	126 128	⊢ B →	0.37 0.54	[0.28;0.46] [0.45;0.63]
Alshami, AA Andrikopoulou, M	46	158		0.29	[0.22;0.37]
Noh, JY Kong, W	53 45	199 473	H - ■:	0.27 0.10	[0.21;0.33] [0.07;0.13]
Wang, Y2	63	279	 -	0.23	[0.18;0.28]
Pham, TQ	89 108	208 231		0.43 0.47	[0.36;0.50] [0.40;0.53]
Kumar, R	100				
Overall effect		6616	[0.03;0.67]	0.2	[0.17;0.25]
			0 0.25 0.5 0.75 1		

S3 Figure. Risk of bias and reporting quality of observational studies assessing proportion of asymptomatic and pre-symptomatic SARS-CoV-2 infection [11,12]


	iteria for inclusion	is for	atus ν-up ω	utive on of a	sion ants	fthe ics of a	nical ation coms)	sa do du-w	8b	fthe clinic phics	and nator lable	11a	tio o u	tt ack in ate in all sof
Author	Clear criteria for inclusion	RT-PCR diagnosis for all participants	Asymptomatic status at start of follow-up	Consecutive inclusion of participants	Complete inclusion of participants	Reporting of the demographics of participants	Reporting of clinical information (symptoms)	Symptom status of cases at the end of follow-up	Adequate follow-up	Reporting of the site/clinic demographics	Numerator and denominator available	Study population adequate sample of the source	Study population adequate sample of the target population	The assessment of the secondary attack rate was adequate and similar in all groups flow risk of
Contact investigations Tong, ZD	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
735: Huang, R	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No No No	NA NA
344: Jiang, XL 372: Jiang, X	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
36: Liao, J 22: Hu, Z	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
42: Luo, SH	Yes Yes	Yes	Yes	Yes	No	No	Yes	Yes Yes	Yes	Yes	Yes	Yes	No	NA
11: Chan, JF 180: Ye, F	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No No No No No	NA NA
4: Bai, Y	Yes	Yes	Yes	Yes	Yes	No No	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
374: Luo: Y 142: Zhang, J	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
389: Zhang, B	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
449: Huang, L 54: Qian, G	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes No	Yes Yes	Yes Yes	No No	NA NA
414: Gao, Y	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No No	NA
563: Chaw, L Contact investigations,	Yes aggregated	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
599: Hijen, P	Yes	Yes	Yes	Yes	No Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA NA
665: Brandstetter, S 821: Zhang, W2	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	No Yes	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No Yes	NA Yes
477: Cheng, HY 249: Wang, Z	Yes	Yes Yes	Yes Yes	Yes Unclear	Yes	No No	No Yes	Yes Unclear	Yes Unclear	Yes Yes	Yes Yes	Yes Unclear	Yes	Yes NA
597: Wu, J	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No No	NA
122: Luo, L 443: Bi, Q	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes NA
908: Yang, R	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	NA NA
Outbreak investigation 242: Danis, K	s Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
713: Böhmer, MM	Yes	Yes	Yes	Yes	Yes	No No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	NA
763: Roxby, AC 152: Yang, N	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	No Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	No No	NA NA
396: Schwierzeck, V	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
376: Arons, MM 354: Park, SY	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	No No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No Yes	NA Yes
849: Dora, AV	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
265: Tian, S 899: Solbach, W	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	Yes No	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	NA NA
1003: Graham, N	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
696: Pham, TQ Screening	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	NA
317: Hoehl, S	Yes	Yes	Yes	Yes	Yes	No	No No	Yes	Yes	Yes	Yes	Yes	No No	NA NA
170: Chang, L 224: Arima, Y	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	No	Yes Yes	Yes Yes	No Yes	Yes Yes	Yes No	No	NA NA
598: Rivett, L 622: Treibel, TA	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	No No	No No	Yes Yes	Yes Yes	Yes	Yes Yes	Yes Unclear	No No	NA NA
294: Lavezzo, E	Unclear	Yes	Yes	Unclear	No No	No	No	Yes	Yes	Yes	Yes	Yes	Unclear	NA
593: Lombardi, A 278: Lytras, T	Yes	Yes Yes	Yes No	Yes Yes	Yes Yes	No No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
Hospitalised adults			110				103					103		
204: Pongpirul, WA 216: Zou, L	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Unclear	Yes Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Unclear	No No	NA NA
521: Qiu, C	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
761: Zhou, R 664: Chang, MC	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No Yes	No No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Unclear Yes	No No	NA NA
233: Zhou, X	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No No	NA
765: Angelo Vaira, L 187: Wang, X	Yes Yes	Unclear Yes	Yes Yes	Yes Yes	Yes Yes	Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No	NA NA
506: Wong, J 434: Xu, T	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	No Yes	No Yes	Yes Yes	Yes Yes	No Yes	Yes Yes	Yes Yes	No No	NA NA
729: London, V	Yes	Yes	Yes	Yes	Unclear	Yes	No	Yes	Yes	Yes	Yes	Yes	No	NA
164: Tabata, S 832: Andrikopoulou, M	Yes	Yes Yes	Yes Yes	Yes Yes	Yes	Yes No	Yes Yes	Yes Yes	No Yes	Yes Yes	Yes Yes	No Yes	No No	NA NA
797: Noh, JY	Unclear	Yes	Yes	Unclear	Unclear	No	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	NA
818: Kumar, R 267: Meng, H	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No Unclear	Yes Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
491: Zhang, Z	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	No	NA
834: Al-Shamsi, HO 71: Wang, Y1	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
Hospitalised children														
299: See, KC 275: Tan, YP	Yes	Yes	Yes	Yes	Yes	Yes Yes	Yes	Yes	Yes	Yes	Yes Yes	Unclear Yes	No No	NA NA
334: Tan, X 769: Melgosa, M	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes Yes	Yes	Yes	No No	NA NA
843: Wu, HP	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	Yes Yes	Yes Yes	Yes Yes	Yes	Yes Yes	Yes Yes	No	NA NA
481: Song, W 653: Bai, K	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No No	NA NA
382: Xu, H	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Unclear	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Unclear	Yes Yes	Yes Yes	No	NA NA
141: Qiu, H 556: Lu, Y	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Unclear	Yes Yes	Yes Yes	Unclear Yes	Unclear Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
Hospitalised adults and	children	163	1 163	103	Unicidal	163	163	163	163	1 163	163	163		
637: Merza, MA 328: Yongchen, Z	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	No No	NA NA
585: Ma, Y	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
559: Kim, SE 856: Choe, PG	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes No	Unclear No	NA NA
981: Sharma, AK	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	NA
745: Zhang, W3 726: Alshami, AA	Unclear Yes	Yes Yes	Yes Yes	Yes Yes	No Yes	No No	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Yes Yes	Unclear Yes	No Unclear	NA NA
936: Kong, W	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	NA
778: Wang, Y2	Yes	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	No	NA

Adapted from two published assessment tools, citations refer to reference list in main text.

11. Joanna Briggs Institute checklist for case series, questions 1 to 10 (http://joannabriggs.org/research/critical-appraisal-tools.html]

12. Boyle MH. Guidelines for evaluating prevalence studies. Evidence Based Men Health 1999;1:37-40, questions 11a and 11t

Question 12 added by authors to assess risk of selection bias for participants in studies reporting secondary attack rate



S4 Figure: Review question 2, forest plot of included studies, by study precision

Pongpirul, WA	Study	Events	Total	Prop.	95% CI
Tong, ZD [cluster:1] 1 2	See, KC Pongpirul, WA Zou, L Tan, YP Tan, X Melgosa, M Wu, HP Merza, MA Yongchen, Z Song, W Qiu, C Bai, K Zhou, R Xu, H Qiu, H Ma, Y Kim, SE Chang, MC Zhou, X Angelo Vaira, L Choe, PG Wang, X Wong, J Xu, T London, V Sharma, AK Zhang, W3 Lu, Y Tabata, S Alshami, AA Andrikopoulou, M Noh, JY Kong, W Wang, Y2 Kumar, R Subgroup estimate	1 1 2 2 3 3 6 5 8 9 11 10 10 10 10 15 14 16 15 22 215 26 29 33 69 46 53 45 63	11 18 10 13 16 23 15 21 16 104 25 31 32 36 47 71 139 328 345 113 1012 138 342 68 234 110 104 128 158 199 473 279 231	0.09 0.06 0.20 0.15 0.19 0.13 0.40 0.24 0.50 0.05 0.32 0.29 0.34 0.28 0.23 0.14 0.07 0.03 0.03 0.13 0.01 0.12 0.04 0.32 0.92 0.19 0.26 0.32 0.54 0.29 0.27 0.10 0.23 0.47	[0.01;0.81] [0.00;0.41] [0.00;0.27] [0.03;0.56] [0.02;0.45] [0.04;0.46] [0.03;0.34] [0.16;0.68] [0.08;0.47] [0.25;0.75] [0.02;0.11] [0.15;0.54] [0.14;0.48] [0.19;0.53] [0.14;0.45] [0.12;0.38] [0.07;0.24] [0.04;0.13] [0.01;0.06] [0.01;0.06] [0.01;0.05] [0.08;0.21] [0.01;0.05] [0.08;0.21] [0.01;0.02] [0.07;0.18] [0.02;0.07] [0.22;0.45] [0.88;0.95] [0.13;0.27] [0.18;0.36] [0.23;0.42] [0.45;0.63] [0.21;0.33] [0.21;0.33] [0.14;0.25]
Graham, N 46 126 □ 0.37 [0.28;0.28] Pham, TQ 89 208 □ 0.43 [0.36;0.28] Subgroup estimate 1585 ■ 0.22 [0.17;0.28]	Tong, ZD [cluster:1] Hoehl, S Huang, R Jiang, XL [cluster:2] Jiang, XL [cluster:2] Tong, ZD [cluster:2] Tong, ZD [cluster:2] Hu, Z Luo, SH Jiang, XL [cluster:3] Chan, JF Liao, J [cluster:3] Chan, JF Liao, J [cluster:1] Ye, F Bai, Y Luo, Y Hijnen, D Danis, K Böhmer, MM Chang, L Zhang, B Huang, L Qian, G Roxby, AC Yang, N Schwierzeck, V Brandstetter, S Arima, Y Zhang, W2 Arons, MM Cheng, HY Gao, Y Wang, Z Park, SY Dora, AV Rivett, L Tian, S Wu, J Luo, L Treibel, TA Solbach, W Bi, Q Lavezzo, E Yang, R Lombardi, A Graham, N Pham, TQ Subgroup estimate	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 3 3 3 4 4 4 4 5 5 5 6 6 11 13 6 4 5 7 7 8 6 10 12 36 12 12 47 22 15 47 97 19 30 24 87 73 87 87 87 87 87 87 87 87 87 87 87 87 87	0.50 0.50 0.50 0.50 0.50 0.50 0.33 0.33	[0.01;0.99] [0.01;0.99] [0.01;0.99] [0.01;0.99] [0.01;0.91] [0.01;0.91] [0.09;0.99] [0.01;0.81] [0.01;0.81] [0.01;0.81] [0.01;0.81] [0.01;0.81] [0.01;0.72] [0.01;0.72] [0.01;0.72] [0.00;0.64] [0.36;1.00] [0.00;0.36] [0.00;0.30] [0.07;0.93] [0.05;0.85] [0.04;0.71] [0.03;0.65] [0.04;0.71] [0.03;0.65] [0.01;0.19] [0.10;0.65]

Study	Events	Total		Prop.	95% CI
Contact investigation Tong, ZD [cluster:1] Huang, R Jiang, XL [cluster:2] Jiang, XL [cluster:3] Jiang, X Tong, ZD [cluster:2] Hu, Z Luo, SH Jiang, XL [cluster:1] Chan, JF Ye, F Bai, Y Luo, Y Zhang, J Zhang, B Huang, L Qian, G Gao, Y Subgroup estimate	1 1 1 1 1 1 1 1 1 1 5 2 2 2 2 2 6	2 2 2 2 3 3 4 4 4 5 5 6 6 5 7 7 8 15 9 9		0.50 0.50 0.50 0.50 0.33 0.67 0.25 0.25 0.25 0.20 0.17 0.83 0.40 0.29 0.29 0.25 0.40 0.25	[0.01;0.99] [0.01;0.99] [0.01;0.99] [0.01;0.91] [0.09;0.99] [0.01;0.81] [0.01;0.81] [0.01;0.81] [0.01;0.72] [0.01;0.72] [0.00;0.64] [0.36;1.00] [0.05;0.85] [0.04;0.71] [0.04;0.71] [0.04;0.71] [0.03;0.65] [0.16;0.68] [0.22;0.49]
Contact investigation, a Hijnen, D Brandstetter, S Zhang, W2 Cheng, HY Wang, Z Wu, J Bi, Q Yang, R Subgroup estimate	1 2 4 4 4 8 17 33	11 36 12 22 47 83 87 78 376		0.09 0.06 0.33 0.18 0.09 0.10 0.20 0.42 0.16	[0.00;0.41] [0.01;0.19] [0.10;0.65] [0.05;0.40] [0.02;0.20] [0.04;0.18] [0.12;0.29] [0.31;0.54] [0.09;0.26]
Outbreak investigation Danis, K Böhmer, MM Roxby, AC Schwierzeck, V Arons, MM Park, SY Dora, AV Graham, N Subgroup estimate	1 1 3 2 3 4 6 46	13 16 6 12 47 97 19 126 336		0.08 0.06 0.50 0.17 0.06 0.04 0.32 0.37 0.15	[0.00;0.36] [0.00;0.30] [0.12;0.88] [0.02;0.48] [0.01;0.18] [0.01;0.10] [0.13;0.57] [0.28;0.46] [0.08;0.26]
Screening Hoehl, S Chang, L Arima, Y Rivett, L Treibel, TA Subgroup estimate	1 2 4 5 12	2 4 12 30 44 92		0.50 0.50 0.33 0.17 0.27 0.29	[0.01;0.99] [0.07;0.93] [0.10;0.65] [0.06;0.35] [0.15;0.43] [0.14;0.50]
Hospitalised adults Pongpirul, WA Zou, L Qiu, C Zhou, R Zhou, X Angelo Vaira, L Wang, X Wong, J Xu, T London, V Andrikopoulou, M Noh, JY Subgroup estimate	1 1 5 9 10 10 14 16 15 22 46 53	11 18 104 31 328 345 1012 138 342 68 158 199 2754		0.09 0.06 0.05 0.29 0.03 0.03 0.01 0.12 0.04 0.32 0.29 0.27 0.09	[0.00;0.41] [0.00;0.27] [0.02;0.11] [0.14;0.48] [0.01;0.06] [0.01;0.05] [0.01;0.02] [0.07;0.18] [0.02;0.07] [0.22;0.45] [0.22;0.37] [0.21;0.33] [0.06;0.14]
Hospitalised children See, KC Tan, YP Tan, X Melgosa, M Wu, HP Song, W Bai, K Qiu, H Lu, Y Subgroup estimate	1 2 2 3 3 8 8 10 29	4 10 13 16 23 16 25 36 110 253		0.25 0.20 0.15 0.19 0.13 0.50 0.32 0.28 0.26 0.24	[0.01;0.81] [0.03;0.56] [0.02;0.45] [0.04;0.46] [0.03;0.34] [0.25;0.75] [0.15;0.54] [0.14;0.45] [0.18;0.36] [0.14;0.38]
Hospitalised adults & ca Merza, MA Yongchen, Z Ma, Y Kim, SE Choe, PG Kong, W Wang, Y2 Subgroup estimate	hildren 6 5 11 10 15 45 63	15 21 47 71 113 473 279 1019		0.40 0.24 0.23 0.14 0.13 0.10 0.23 0.18	[0.16;0.68] [0.08;0.47] [0.12;0.38] [0.07;0.24] [0.08;0.21] [0.07;0.13] [0.18;0.28] [0.11;0.30]
Overall estimate		4920	0 0.25 0.5 0.75 1	0.18	[0.14;0.22]

S7 Figure. Relevance and credibility of mathematical modelling studies assessing contribution of asymptomatic and pre-symptomatic infection to SARS-CoV-2 transmission

	1	2	3	4	5	6	7	8	9	10	11	12	13
Author	Is the population relevant?	Are any critical interventions missing?	Is the context (settings and circumstances) applicable?	Is external validation of the model sufficient to make its results credible for your decision?	Is internal verification of the model sufficient to make its results credible for your decision?	Does the model have sufficient face validity to make its results credible for your decision?	Is the design of the model adequate for your decision problem?	Are the data used in populating the model suitable for your decision problem?	Were the analyses performed using the model adequate to inform your decision problem?	Was there an adequate assessment of the effects of uncertainty?	Was the reporting of the model adequate to inform your decision problem?	Was the interpretation of results fair and balanced?	Were there any potential conflicts of interest?
Ferretti, L	Partial	NA	Yes	No	Yes	Yes	Yes	Partial	Yes	Yes	Yes	No	No
Ganyani, T	Partial	NA	Yes	No	Yes	Yes	Yes	Partial	Yes	Partial	Yes	Partial	No
Zhang, W	Partial	NA	Yes	No	Yes	No	Partial	Partial	No	No	No	No	Unclear
He, X	Partial	NA	Yes	No	Yes	Yes	Yes	Partial	Yes	Yes	Partial	Yes	No
Emery, JC	Partial	NA	Yes	Partial	Yes	Yes	Partial	Partial	Yes	Yes	Yes	Yes	No
Casey, M	Yes	NA	Yes	Partial	Yes	Partial	Yes	Yes	Partial	Yes	Yes	Yes	No
Kim, Y	Partial	NA	Yes	No	Yes	Yes	Yes	Partial	Yes	Yes	Yes	Partial	No
Peak, CM	Yes	NA	Partial	No	Yes	Partial	Yes	No	Partial	Partial	Partial	Yes	No

 $\label{lem:checklist} \textbf{Checklist from ref 13. Jaime Caro J, et al. Value Health 2014;} \textbf{17:174-82.}$

Partial: item is partially addressed

NA: Not applicable

PRISMA 2009 Checklist

Section/topic	#	Checklist item					
TITLE							
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title				
ABSTRACT							
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	Abstract				
INTRODUCTION							
Rationale	3	Describe the rationale for the review in the context of what is already known.	1-2				
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3				
METHODS							
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	1				
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	3				
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	2				
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	2, S1 Text				
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4				
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4				

PRISMA 2009 Checklist

Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	6
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I²) for each meta-analysis.	7
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	Not done
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	7
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	1, S1 Fig
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1, Table 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	3, S3 Fig, S7 Fig
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Fig 1, Fig 2, Fig 3, Fig 4
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	4, 5, 6
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Not done
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	8
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	1, 5-7
		· · · · · · · · · · · · · · · · · · ·	

PRISMA 2009 Checklist

Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	3
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	8
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	Metadata

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097